GLP-1 side effects: timing, common symptoms, and red flags

What the labels say about mechanism and GI effects

Wegovy and Zepbound both delay gastric emptying. Their labels also state that semaglutide and tirzepatide decrease calorie intake, likely through appetite effects, and both list gastrointestinal adverse reactions. The labels do not establish one explanation for every symptom. [1] [2]

Both products use stepwise escalation schedules intended to reduce gastrointestinal adverse reactions. The schedule and any dose change remain medication-specific decisions for the prescriber and current label. [1] [2]

The common side effects

The current Wegovy and Zepbound labels list the effects below among adverse reactions observed in their trials. Rates differ by product, dose, trial, and population, so this is not a personal risk estimate or a head-to-head comparison. [1] [2]

Hair loss: what a new review of semaglutide trials found

The short answer: a systematic review and meta-analysis of randomized trials, published in Cureus in September 2026, found that hair loss was reported more often in people given semaglutide than in comparison groups, but the authors rate that evidence as low certainty. It found no clear difference in injection-site reactions.[5]

The authors, dermatology and community-medicine researchers in India, registered their protocol in advance (PROSPERO CRD420261464289) and searched PubMed, Europe PMC, trial registers, sponsor reports and regulatory sources through September 9, 2026. Thirty-one trials contributed checked outcome data; the main analysis compared semaglutide with placebo or a shared control.[5]

• Alopecia or hair loss: reported in 191 of 11,564 semaglutide recipients and 36 of 9,799 comparison participants across nine comparisons, an odds ratio of 2.92 (95% confidence interval 1.99 to 4.27), rated low certainty. The result held when the largest cardiovascular outcomes trial was left out.[5] Our arithmetic on those pooled counts is about 1.7% versus 0.4%; that is a raw total across different trials, not a personal risk estimate.
• Injection-site reactions: 156 of 5,066 semaglutide recipients versus 114 of 3,483 comparison participants, an odds ratio of 0.86 (0.67 to 1.11), rated very low certainty. The authors call semaglutide’s effect here “uncertain.”[5]

Limits. The authors say their method, pooling only trials that published usable event counts, “does not resolve selective non-reporting or incomplete event ascertainment,” and that the findings “do not establish a hair-loss mechanism.” They also note that skin side effects are reported inconsistently across trials. We read the abstract through PubMed; the authors report no outside funding and no financial conflicts.[5]

Our analysis: this is a signal worth tracking, not proof that semaglutide itself causes hair loss. If you notice more shedding, note when it started and any change in diet or weight, and bring that to your prescriber rather than changing your medicine on your own.

How many people stop semaglutide because of side effects?

The short answer: in an updated meta-analysis of 10 placebo-controlled semaglutide trials in adults with overweight or obesity but without diabetes, about 6% of people on semaglutide stopped treatment because of adverse events, compared with about 3% on placebo.[6]

The review, published in the Journal of Diabetes & Metabolic Disorders on October 31, 2026, registered its protocol in advance (PROSPERO CRD420261338170) and searched PubMed, Embase, the Cochrane Library, Web of Science and ClinicalTrials.gov through February 28, 2026. It pooled 10 randomized trials with 7,131 participants.[6]

• Stopping because of adverse events: 6.0% with semaglutide versus 3.0% with placebo in aggregate, a risk ratio of 1.86 (95% confidence interval 1.41 to 2.45), with no measurable heterogeneity across 10 trials.[6]
• Any adverse event: 90.0% versus 85.0%, a risk ratio of 1.06 (1.03 to 1.10). Most people in both groups reported at least one adverse event.[6]
• Serious adverse events: a risk ratio of 1.16 (0.90 to 1.51). The authors say this estimate is imprecise: it did not establish a clear difference, and the interval is still compatible with a potentially important increase in risk.[6]

Limits. The authors rate the certainty of evidence for the main weight outcomes as low, report substantial heterogeneity between trials, and note that some concerns remained about how trials captured cardiovascular and psychiatric disorders. They caution that the pooled figures are averages that may not apply equally across doses, formulations, treatment lengths or patient groups. We read the abstract through PubMed; the authors declare no competing interests.[6]

Our analysis: in these trials most people who started semaglutide did not stop because of side effects, but stopping for that reason was roughly twice as common as on placebo. Trial participants had scheduled follow-up, so real-world rates may differ. If side effects make you consider stopping, a dated record of what happened and when gives your prescriber something concrete to work with; decisions about continuing belong with them.

Do GLP-1 drugs affect bone density?

The short answer: a new meta-analysis of placebo-controlled trials found a small, borderline drop in lumbar spine bone mineral density and a rise in a blood marker of bone breakdown on GLP-1 receptor agonists, with no clear change at the hip. Almost all of the trials tested older GLP-1 drugs, so the authors say the results cannot be applied to newer, stronger weight-loss medicines.[7]

The review, published in Bone on November 2, 2026, searched Scopus, Web of Science, Embase and PubMed through May 12, 2026 for placebo-controlled randomized trials lasting 12 to 52 weeks. Eleven trials were pooled and one more was described narratively: 11 tested exenatide, dulaglutide or liraglutide and one tested semaglutide. The authors found no eligible placebo-controlled bone trials of the semaglutide obesity dose or of tirzepatide.[7]

• Lumbar spine bone density: slightly lower than placebo (weighted mean difference -0.02 g/cm², 95% confidence interval -0.03 to -0.00; 3 trials, 222 people; moderate certainty).[7]
• Bone breakdown marker (CTX): higher than placebo (0.05 μg/L, 0.01 to 0.08; 6 trials, 439 people; low certainty).[7]
• Hip and femoral neck bone density: no significant difference (low to very low certainty).[7]
• Inflammation (hs-CRP): lower than placebo (-0.49 mg/L, -0.97 to -0.00; low certainty).[7]

Limits. The pooled trials were small and short, certainty ranged from moderate to very low, and the authors call for dedicated long-term skeletal safety trials of the newer agents. We read the abstract through PubMed; the authors declare no competing interests.[7]

Our analysis: the spine finding is small and borderline, and bone markers are not fractures, so this does not show that GLP-1 drugs weaken bones. It does mean the bone question for today’s higher-potency weight-loss drugs is still open. If bone health is a concern for you, that is a conversation for your prescriber, and a dated record of your treatment helps them see the full picture.

What the labels say about timing

Neither cited label provides a universal week-by-week side-effect timeline. The strongest source-supported pattern is tied to escalation, and the two labels describe it differently:

• Wegovy injection: its trial section says gastrointestinal reactions were most frequently reported during dosage escalation. [1]
• Zepbound: its label says most nausea, vomiting, and diarrhea events occurred during dosage escalation and decreased over time. [2]
• For an individual: neither statement guarantees when a symptom will start, how long it will last, or whether it is caused by the medicine.

Red flags: when to seek medical care

• Severe or persistent abdominal pain, sometimes radiating to the back and with or without nausea or vomiting, is listed as a possible sign of pancreatitis.
• Nausea, vomiting, or diarrhea that does not go away can lead to dehydration and kidney injury; the medication guides tell patients to contact their healthcare provider.
• Vomiting or being unable to eat or drink, especially while eating very little: Japan’s regulator reported ambulance cases of ketosis and ketoacidosis in people using these drugs to slim down (see below).[3]
• Severe stomach problems: both medication guides say to tell a healthcare professional about stomach problems that are severe or do not go away. Both labels also report postmarketing ileus, intestinal obstruction, and severe constipation including fecal impaction.
• Signs of a serious allergic reaction, including swelling of the face, lips, tongue, or throat or trouble breathing or swallowing, require urgent care.
• Symptoms of low blood sugar matter especially when these medicines are used with insulin or an insulin secretagogue such as a sulfonylurea, because the labels describe increased risk with those combinations.
• A neck lump, persistent hoarseness, trouble swallowing, or shortness of breath appears in the labels' counseling language about thyroid tumors. Both products are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.
• Before surgery or a procedure using anesthesia or deep sedation, tell the care team you take the medicine. Both labels describe rare postmarketing pulmonary aspiration reports and say evidence is insufficient to define a universal mitigation plan.

Vomiting and not eating: Japan’s October 2026 ketosis alert

The short answer: Japan’s drug regulator, the Pharmaceuticals and Medical Devices Agency (PMDA), warned clinicians on October 30, 2026 that it has several reports of people who used GLP-1 or GIP/GLP-1 drugs to slim down while eating very little, vomited repeatedly, and were taken to hospital by ambulance with ketosis or ketoacidosis. Its instruction to clinicians is to tell patients to stop the drug at once and seek medical care if they vomit or cannot take in food or water.[3]

PMDA’s alert (No. 18, October 2026) says some medical institutions in Japan prescribe these drugs “for aesthetic and slimming purposes” rather than for type 2 diabetes or obesity, and that safety and efficacy for that off-label use “have not been established.” It explains ketosis as a build-up of ketone bodies from extreme dietary restriction that can progress to ketoacidosis, which “may result in disturbed consciousness and life-threatening conditions, requiring urgent treatment.”[3] What the alert reports:[3]

• Report counts for slimming use (Japan’s adverse-event database, April 2004 to May 2026): 28 gastrointestinal, 17 ketosis or ketoacidosis, 14 low blood sugar and 11 pancreatitis events. Of those 70, Mounjaro (tirzepatide) accounted for 56, including all 17 ketosis events; semaglutide sold as Ozempic or Rybelsus for 12; and liraglutide (Victoza) for 2. Zepbound and Wegovy had 0 in every row. PMDA notes the counts “do not represent the incidence of adverse reactions.”[3]
• Three ambulance cases, all women in their 20s using the drug for weight control, all recovered. One, with a history of anorexia nervosa, got the drug through an online healthcare service at a BMI of about 18 and was hospitalized with starvation ketosis about two months later at a BMI of about 16. One developed fever, frequent vomiting and could not eat after her second dose and was hospitalized on day 10 with starvation ketoacidosis. One was already cutting carbohydrates, got the drug online without nutrition counselling, and was hospitalized about a month later with starvation ketoacidosis.[3]

Japan’s Ministry of Health, Labour and Welfare (MHLW), whose warning page the alert links, says it notified medical institutions and manufacturers about proper use on June 16, 2026 and asked for that notice to be re-circulated on October 14, 2026 after a ketosis warning from the Japan Society for the Study of Obesity. The page also says person-to-person resale of these drugs online is illegal in Japan, and that harm from beauty or slimming use is very likely not to qualify for Japan’s drug side-effect relief payments.[4]

Limits. These are spontaneous reports from one country. The alert does not say how many people used each product for slimming, so the counts cannot show that one drug is riskier than another. We read PMDA’s English version, which says the Japanese original prevails if they differ, and the MHLW page in Japanese.[3][4]

Our analysis: the US Wegovy and Zepbound medication guides already warn about nausea, vomiting or diarrhea that does not go away and the dehydration it can cause. What these Japanese reports add is that combination in people who were also eating very little, two of whom got the drug online. If you can’t keep food or fluids down, contact a healthcare professional promptly. Side effects can be reported to FDA’s MedWatch program.[1] [2] [3]

What to discuss with your prescriber

The labels support a short, non-prescriptive checklist. Your prescriber and the current product label determine medication-specific decisions.

• Persistent gastrointestinal symptoms: both medication guides tell patients to report symptoms that do not go away.
• Fluid loss: both guides advise drinking fluids to reduce dehydration risk from nausea, vomiting, or diarrhea.
• The prescribed escalation plan: follow the medication-specific label and prescriber; do not change the dose or timing from this page.
• Planned anesthesia or deep sedation: make sure the procedural team knows which medicine you use.

The source for each point is the current Wegovy or Zepbound prescribing information and medication guide. [1] [2]

Side effects vary by medication

Wegovy and Zepbound have overlapping but not identical adverse-reaction tables, warnings, and schedules. For medication-specific context, use the current label and start with the relevant pillar page: [1] [2]

• Semaglutide — a GLP-1 receptor agonist.
• Tirzepatide — a dual GIP/GLP-1 receptor agonist.

FAQ

Do GLP-1 side effects go away?

The labels do not promise one timeline. In Wegovy injection trials, gastrointestinal reactions were most frequent during dosage escalation. Zepbound says most nausea, vomiting, and diarrhea events occurred during escalation and decreased over time. Persistent or severe symptoms belong with a healthcare professional, not a generic timeline.

Are side effects worse after a dose increase?

Both labels connect escalation with gastrointestinal tolerability. In Wegovy injection trials, gastrointestinal reactions were most frequent during escalation; Zepbound reports that most nausea, vomiting, and diarrhea events occurred during escalation. That trial pattern cannot predict one person's response.

Does this page tell me what dose to take?

No. This page is educational and focused on understanding and tracking side effects. Dosing, titration, and switching decisions belong with your prescriber.

When should I contact a healthcare professional?

Promptly report severe or persistent abdominal pain, gastrointestinal symptoms that do not go away, or symptoms of a serious allergic reaction. The current label for the medicine is the source of truth for its warning signs.

Can GLP-1 drugs cause ketosis or ketoacidosis?

Japan’s drug regulator, PMDA, said in an October 2026 alert that it has several reports of people using GLP-1 or GIP/GLP-1 drugs for slimming while eating very little who vomited repeatedly and were taken to hospital with ketosis or ketoacidosis. Its table lists 17 such reports from 2004 to May 2026; these are report counts, not rates. PMDA tells clinicians to have patients stop the drug and seek care if they vomit or cannot eat or drink. Talk to your prescriber about any symptoms like these.

Sources opened and checked

1. Current Wegovy prescribing information and medication guide, DailyMed.
2. Current Zepbound prescribing information and medication guide, DailyMed.
3. Pharmaceuticals and Medical Devices Agency (Japan). PMDA Alert for Proper Use of Drugs No. 18, October 2026: Request for Proper Use of GLP-1 Receptor Agonists and GIP/GLP-1 Receptor Agonists (English version; posted October 30, 2026). Listed on PMDA’s alert index.
4. Ministry of Health, Labour and Welfare (Japan). Warning page on health harm from cosmetic and slimming use of type 2 diabetes drugs such as Mounjaro and Rybelsus (in Japanese).
5. Ganjre S, Borah L, Khardenavis A. Cutaneous Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus. 2026;18(9):e117270. doi:10.7759/cureus.117270. PMID 42966951; PMCID PMC13722923. Abstract read via PubMed.
6. Wajid R, Kumar R, Muneer M, et al. Efficacy and safety of semaglutide versus placebo in adults with overweight or obesity without diabetes: updated meta-analysis of randomized trials. J Diabetes Metab Disord. 2026;25(2):305. doi:10.1007/s40200-026-02108-x. PMID 42968774; PMCID PMC13723587. Abstract read via PubMed.
7. Safargar M, Ahmadi N, Prabahar K, Zandi R, Varkaneh HK. The effect of glucagon-like peptide-1 receptor agonists on bone metabolism: a systematic review and meta-analysis of randomized placebo-controlled trials of predominantly first-generation agents. Bone. 2026:118160. doi:10.1016/j.bone.2026.118160. PMID 42971377. Abstract read via PubMed.

Sources 1 and 2 were opened and checked against the claims on this page on October 16, 2026; sources 3 and 4 on October 31, 2026; source 5 on November 1, 2026; source 6 on November 2, 2026; source 7 on November 3, 2026.